Company: SCLXW
Filing Date: 2025-06-24
Form Type: 424B3
Source: 0000950170-25-089447
Chunk: 0

Company: Scilex Holding Co
Filing Date: 2025-06-24
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-275117

PROSPECTUS SUPPLEMENT NO. 2
(to Prospectus dated May 13, 2025)

<div align='center'>SCILEX HOLDING COMPANYUp to 6,685,714 Shares of Common
Stock
________________</div>

This prospectus supplement supplements the prospectus dated May 13, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-275117) for which Post-Effective Amendment No. 2 was filed with the Securities and Exchange Commission on May 7, 2025 and declared effective by the Securities and Exchange Commission on May 13, 2025. This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 23, 2025 (the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement.

The Prospectus and this prospectus supplement relate to the resale from time to time by the selling stockholder named in the Prospectus (including its permitted transferees, donees, pledgees and other successors-in-interest) (the “Selling Stockholder”) of up to an aggregate of 6,685,714 shares of our common stock, par value $0.0001 per share (“Common Stock”), consisting of (i) up to 6,500,000 shares of Common Stock issuable upon exercise of Penny Warrants (as defined below) (such shares issuable upon exercise, the “Penny Warrant Shares”), issued to Oramed Pharmaceuticals Inc. (“Oramed”) pursuant to the Scilex-Oramed SPA (as defined and described below) and (ii) up to 185,714 shares of Common Stock previously issued to Oramed upon exercise of a portion of the Penny Warrants previously issued to Oramed pursuant to the Scilex-Oramed SPA (the “Issued Shares” and together with the Penny Warrant Shares, the “Resale Shares”).

On September 21, 2023 (the “Oramed Closing Date”), we entered into, and consummated the transactions contemplated by that certain Securities Purchase Agreement, dated as of such date, between us and Oramed (the “Scilex-Oramed SPA”).